Copy
See below for a daily digest of the latest Huntington's Disease news!

Investigational Drug, Olesoxime, Seen to Ease Huntingtin Fragmentation in Mouse Model

May 09, 2016 07:00 am | Magdalena Kegel

 

Huntington's mouse modelBeneficial effects of the investigational neuroprotective drug olesoxime have mainly been attributed to its effects on mitochondria, but new research suggests it also blocks calpain — a molecule directly involved in Huntington’s disease. The findings indicate that exploring the drug’s exact mechanism might bring scientists closer to effective treatments for Huntington’s. Olesoxime (Roche Pharmaceuticals) has been […]

The post Investigational Drug, Olesoxime, Seen to Ease Huntingtin Fragmentation in Mouse Model appeared first on Huntington's Disease News.

Read More
share on Twitter Like Investigational Drug, Olesoxime, Seen to Ease Huntingtin Fragmentation in Mouse Model on Facebook

Olesoxime Targets Calpain and May Lead to New Approaches in Huntington’s Treatment

May 06, 2016 01:43 pm | Ines Martins, PhD

 

shutterstock_414749194Olesoxime, a drug shown to have neuroprotective properties, may have beneficial effects in Huntington’s patients through reduction of calpain-mediated huntingtin cleavage, according to the study “The calpain-suppressing effects of olesoxime in Huntington’s disease,” published in the journal Rare Diseases. Olesoxime is a small molecule derived from cholesterol that exerts neuroprotective functions by preventing the activation […]

The post Olesoxime Targets Calpain and May Lead to New Approaches in Huntington’s Treatment appeared first on Huntington's Disease News.

Read More
share on Twitter Like Olesoxime Targets Calpain and May Lead to New Approaches in Huntington’s Treatment on Facebook

FDA Clears Genetically Engineered Mini Pig Model For Use in Research And Drug Development

May 04, 2016 07:00 am | Magdalena Kegel

 

Genetically engineered mini pigs might better model some disease aspects of Huntington’s than mice.Exemplar Genetics announced that the U.S. Food & Drug Administration (FDA) has cleared its low-density lipoprotein receptor (LDLR) mini pig for use in scientific studies. In the future, this type of model could become an invaluable addition to study diseases such as Huntington’s disease, as mouse models have proven insufficient at optimally translating preclinical research to the human setting. The FDA […]

The post FDA Clears Genetically Engineered Mini Pig Model For Use in Research And Drug Development appeared first on Huntington's Disease News.

Read More
share on Twitter Like FDA Clears Genetically Engineered Mini Pig Model For Use in Research And Drug Development on Facebook

Recent Posts

Cutting-edge Research into Huntington’s, Alzheimer’s, Other Diseases to Be Focus of New UCSF Weill Institute for Neurosciences
Lumie Lamps to Aid in Huntington’s Study of Light and Sleep Therapies at Cambridge University
Molecule Shows Potential to Protect Neurons in Early Huntington’s Disease Study
Huntington’s Researcher Wins Inaugural Hermann J. Muller Award from Indiana University Bloomington
Researchers Decrease Accumulation of Damaging Huntington’s Disease Protein Using New Method in Mice

Copyright © 2016 BioNews Inc., All rights reserved.
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences